Riot Games Brazil has named women’s pain reliever brand Buscofem a sponsor for VALORANT Champions Tour (VCT) Game Changers.
Per a release, Brazilian pharma company Hypera Pharma and Riot Games Brazil joined forces against multiple types of pain that women experience, whether sexism in esports or menstrual cramps.
First announced in February, VCT Game Changers is a new VALORANT programme that focuses on creating opportunities and exposure for women and other marginalised genders.
VCT Game Changers kicked off in March and will conclude in June. The second tour will start in July and ends in November. Gaming platform Gamer’s Club will host the four qualifiers, whilst Riot Games Brazil hosts VCT Game Changers.
Carlos Antunes, Head of Esports at Riot Games in Brazil, commented: “We are very excited about Buscofem’s arrival at the VALORANT Champions Tour Game Changers, an initiative that reinforces Riot Games’ commitment to the representation of women within the universe of electronic sports. It is an honour to have the support of a brand that recognizes the importance of an incentive program for the female community.”
Brazilian agency DRUID brokered the partnership between Riot Games Brazil and Buscofem.
“What makes this project strong is the way we manage to map the main pains of women in the gamer world, connect them with the positioning of the brand and translate this into a performance project that helps to give visibility and solve these pains,” Bruna Pastorini, Director of Planning at DRUID told Esports Insider.
Local female gamers have been chosen as ambassadors for the campaign, including Bárbara Gutierrez, Sher Machado, Isadora Basile and Marina Leite.
“In addition to the ambassadors we have chosen with great pride who will help to broaden the voice of this campaign and raise this crucial topic, the communication we build directly benefits the scene and gamers,” Pastorini continued. “This creates a powerful path for the brand to approach this universe by helping to bring a legacy to it—a transformation.”
Esports Insider says: Non-endemic brands always try to enter the esports and gaming scene, and Buscofem found the right spot sponsoring VALORANT Game Changers. Being a traditional female-focused product, the analgesic stays relevant with a younger audience by sponsoring initiatives like this.
About Esportsreporter.com: A leading news channel for all things eSports and gaming. Publishing the most relevant breaking news for esports and gaming including coverage of industry trends and guides on the business of eSports and gaming for investors and aspiring eSports and gaming professionals.
Esportsreporter.com is a wholly owned subsidiary of Appsoft Technologies, Inc. (OTC:ASFT) a publicly traded development stage company aspiring to be a leading contender in the esports, gaming and mobile apps industry.
Safe Harbor Statement
This communication may include certain statements that are not descriptions of historical facts but are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements may include the description of our plans and objectives for future operations, assumptions underlying such plans and objectives, and other forward-looking terminology such as “may,” “expects,” “believes,” “anticipates,” “intends,” “projects,” or similar terms, variations of such terms or the negative of such terms. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein. Such information is based upon various assumptions made by, and expectations of, our management that were reasonable when made but may prove to be incorrect. All of such assumptions are inherently subject to significant economic and competitive uncertainties and contingencies beyond our control and upon assumptions with respect to the future business decisions which are subject to change. Accordingly, there can be no assurance that actual results will meet expectation and actual results may vary (perhaps materially) from certain of the results anticipated herein.